alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 76–100 of 808 studies published 2013 (page 4 of 33) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Functional screening in Drosophila identifies Alzheimer's disease susceptibility genes and implicates Tau-mediated mechanisms

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Human Molecular Genetics 2013-09-25

Using a Drosophila model of Alzheimer's disease (AD), we systematically evaluated 67 candidate genes based on AD-associated genomic loci (P < 10(-4)) from published human genome-wide association studies (GWAS). 1 key finding →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source

Monetary Costs of Dementia in the United States

✓ Peer-reviewed alzhub usefulness score 66 out of 100. New England Journal of Medicine 2013-04-04

Using a nationally representative survey of older Americans with in-home cognitive testing, researchers estimated that dementia cost the US between $157 billion and $215 billion in 2010, depending on how unpaid family caregiving time is valued. 4 key findings →

Design: cohort Participants: 856 Evidence: high

Full summary, score breakdown and related studies → Original source

Mediterranean diet, cognitive function, and dementia: a systematic review

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Epidemiology (Cambridge, Mass.) 2013-07-01

Published studies suggest that greater adherence to Mediterranean diet is associated with slower cognitive decline and lower risk of developing Alzheimer disease. 4 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Journal of hypertension 2013-06-01

Our results support the notion that antihypertensive treatment has beneficial effects on cognitive decline and prevention of dementia, and indicate that these effects may differ between drug classes with ARBs possibly being the most effective. 5 key findings →

Design: systematic review Participants: 15 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

AD dementia risk in late MCI, in early MCI, and in subjective memory impairment

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2013-01-30

SMI and EMCI with self-reported concerns were associated with the same risk of AD dementia, suggesting that pre-LMCI risk conditions should be extended to SMI with concerns. 5 key findings →

Design: cohort study Participants: 2,892 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Much of late life cognitive decline is not due to common neurodegenerative pathologies

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Annals of neurology 2013-07-10

The pathologic indices of Alzheimer disease, cerebrovascular disease, and Lewy body disease accumulate in the brains of older persons with and without dementia, but the extent to which they account for late life cognitive decline remains unknown. 4 key findings →

Design: longitudinal study Participants: 856 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Factors associated with weight loss, low BMI, and malnutrition among nursing home patients: a systematic review of the literature

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Journal of the American Medical Directors Association 2013-04-30

Potentially modifiable factors consistently associated with increased likelihood of weight loss, low BMI, or poor nutrition included depression, impaired function, and poor oral intake. 5 key findings →

Participants: 100 Evidence: low

Full summary, score breakdown and related studies → Original source

Association of visit-to-visit variability in blood pressure with cognitive function in old age: prospective cohort study

✓ Peer-reviewed alzhub usefulness score 66 out of 100. BMJ (Clinical research ed.) 2013-07-29

Higher visit-to-visit variability in blood pressure independent of average blood pressure was associated with impaired cognitive function in old age. 3 key findings →

Design: cohort study Participants: 5,461 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Increased neurofilament light chain blood levels in neurodegenerative neurological diseases

✓ Peer-reviewed alzhub usefulness score 66 out of 100. PloS one 2013-09-20

We developed and validated a novel ECL based sandwich immunoassay for the NfL protein in serum (NfL(Umea47:3)); levels in ALS were more than 20-fold higher than in controls. 2 key findings →

Design: longitudinal study Participants: 20 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Cerebrospinal fluid τ protein in differential diagnosis of Alzheimer's disease and vascular dementia in Chinese population: a meta-analysis

✓ Peer-reviewed alzhub usefulness score 66 out of 100. American journal of Alzheimer's disease and other dementias 2013-10-27

Patients with AD exhibit significantly higher CSF τ protein levels than healthy controls or patients with VaD in the Chinese population. 3 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source

A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II

✓ Peer-reviewed alzhub usefulness score 65 out of 100. The Lancet 2013-10-26

Researchers re-ran the same detailed dementia survey in the same three parts of England twenty years apart. 4 key findings →

Design: cross-sectional Participants: 15,431 Evidence: high

Full summary, score breakdown and related studies → Original source

The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Psychological medicine 2013-03-25

DLB currently accounts for around one in 25 dementia cases diagnosed in the community and one in 13 cases in secondary care. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Inflammatory proteins in plasma are associated with severity of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 65 out of 100. PloS one 2013-06-10

Markers of Alzheimer's disease (AD) are being widely sought with a number of studies suggesting blood measures of inflammatory proteins as putative biomarkers. 4 key findings →

Design: longitudinal study Participants: 350 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep

✓ Peer-reviewed alzhub usefulness score 64 out of 100. JAMA neurology 2013-12-01

Better sleep consolidation attenuates the effect of APOE genotype on incident AD and development of neurofibrillary tangle pathology. 2 key findings →

Design: cohort study Participants: 698 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Biological psychiatry 2013-09-25

Sodium benzoate substantially improved cognitive and overall functions in patients with early-phase AD. 3 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Neurology 2013-04-10

Abnormal levels of all biomarkers were associated with faster time to cognitive impairment, and some participants with abnormal biomarker levels remained cognitively normal for up to 6.6 years. 2 key findings →

Design: longitudinal study Participants: 201 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Pain, depression, and fatigue: loneliness as a longitudinal risk factor

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Health psychology : official journal of the Division of Health Psychology, American Psychological Association 2013-08-19

Two longitudinal studies with different populations demonstrated that loneliness was a risk factor for the development of the pain, depression, and fatigue symptom cluster over time. 4 key findings →

Design: longitudinal study Participants: 115 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Autoimmunity reviews 2013-03-28

Adequate vitamin D supplementation and sensible sunlight exposure to reach optimal vitamin D status are among the front line factors of prophylaxis for the spectrum of disorders. 3 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study

✓ Peer-reviewed alzhub usefulness score 64 out of 100. JAMA neurology 2013-05-01

Significantly more patients with MCI than without MCI at baseline (10 of 37 [27.0%] vs 1 of 145 [0.7%]; relative risk, 39.2 [95% CI, 5.2-296.5]; P Conclusions and relevance Mild cognitive impairment at PD diagnosis predicts a highly increased risk for early dementia. 1 key finding →

Design: cohort study Participants: 182 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed